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Abstract
Syndecans are transmembrane heparan sulphate proteoglycans. Their role in the development of the malignant phenotype
is ambiguous and depends upon the particular type of cancer. Nevertheless, syndecans are promising targets in cancer
therapy, and it is important to elucidate the mechanisms controlling their various cellular effects. According to earlier
studies, both syndecan-1 and syndecan-2 promote malignancy of HT-1080 human fibrosarcoma cells, by increasing the
proliferation rate and the metastatic potential and migratory ability, respectively. To better understand their tumour
promoter role in this cell line, syndecan expression levels were modulated in HT-1080 cells and the growth rate, chemotaxis
and invasion capacity were studied. For in vivo testing, syndecan-1 overexpressing cells were also inoculated into mice.
Overexpression of full length or truncated syndecan-1 lacking the entire ectodomain but containing the four
juxtamembrane amino acids promoted proliferation and chemotaxis. These effects were accompanied by a marked
increase in syndecan-2 protein expression. The pro-migratory and pro-proliferative effects of truncated syndecan-1 were not
observable when syndecan-2 was silenced. Antisense silencing of syndecan-2, but not that of syndecan-1, inhibited cell
migration. In vivo, both full length and truncated syndecan-1 increased tumour growth and metastatic rate. Based on our in
vitro results, we conclude that the tumour promoter role of syndecan-1 observed in HT-1080 cells is independent of its
ectodomain; however, in vivo the presence of the ectodomain further increases tumour proliferation. The enhanced
migratory ability induced by syndecan-1 overexpression is mediated by syndecan-2. Overexpression of syndecan-1 also
leads to activation of IGF1R and increased expression of Ets-1. These changes were not evident when syndecan-2 was
overexpressed. These findings suggest the involvement of IGF1R and Ets-1 in the induction of syndecan-2 synthesis and
stimulation of proliferation by syndecan-1. This is the first report demonstrating that syndecan-1 enhances malignancy of a
mesenchymal tumour cell line, via induction of syndecan-2 expression.
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Introduction
Syndecans are transmembrane proteoglycans bearing glycos-
aminoglycan (GAG) chains on their extracellular protein domain
[1]. The ectodomain and its GAG chains have been reported to
bind several extracellular matrix components [2] and other, cell
surface proteins [3,4,5]. In this way, syndecans function as
modulators of stromal function and mediators of cell adhesion,
although the precise modes of action remain elusive [6,7]. The
biological activity of syndecans is further modulated by proteolytic
shedding, whereby the ectodomain with its GAG chains is
liberated and becomes a soluble effector. The truncated core
protein remains embedded in the cell membrane, although its fate
and cellular function mediated by the remnant core protein is
unclear [8].
Syndecan-1 (CD138) expression is typical of epithelia [9], while
syndecan-2 is confined to mesenchymal cells [10]. Although
characteristic to the epithelium, syndecan-1 has also been detected
in the condensing mesenchyme during tooth [11,12], limb [13]
and lung [10] morphogenesis, in the adherent stages of B
lymphocyte maturation [14], or in confluent cultures of human
foetal lung fibroblasts [15].
Dysregulation of syndecan expression has been reported during
tumour formation and progression. In a number of neoplasms,
expression patterns of syndecan-1 [2] and syndecan-2 [16]
characteristically correlate with the tumour stage and grade.
While an extensive number of studies investigated the role of
syndecans in carcinomas, little is known about their function in
tumours of mesenchymal origin.
A number of mesenchymal tumours, especially the ones that
show epitheloid morphology, express syndecan-1 [17]. In malig-
nant mesothelioma, a connective tissue tumour with partial
epitheloid differentiation, syndecan-1 is rarely expressed, and its
presence is associated with a more epitheloid phenotype and
longer survival [18,19,20]. Similarly, cultured malignant meso-
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cells, regardless of their phenotypic differentiation [21].
Overexpression of syndecan-2 enhances migration and invasion
of HT-1080 cells into Matrigel [22]. In another type of
mesenchymal tumour, osteosarcoma, syndecan-2 expression is
reduced compared to that in osteoblasts and osteocytes in normal
bone, and the expression of the proteoglycan sensitises tumour
cells to basal and chemotherapy-induced apoptosis [23,24].
Taken together, syndecans appear to be important players in
oncogenesis therefore potential therapeutic targets in cancer [25].
Thus, identification of clinically relevant agonists or antagonists
and understanding the molecular mechanisms underlying their
action is of paramount importance. Earlier we reported that
syndecan-1 increases proliferation and metastatic ability of HT-
1080 cells [26]. In the current report, we expanded the scope of
the studies by focusing on additional syndecan paralogues and
their fine interplay.
Figure 1. Detection of FullEGFP and 78Sig constructs and their effects on the expression and shedding of syndecan-1 in transfected
HT-1080 cells. (A) FullEGFP represents the full-length syndecan-1/EGFP coding construct; 78Sig denotes the truncated syndecan-1 variant. ED,
ectodomain; TM, transmembrane domain; CD, cytoplasmic domain. (B) Syndecan-1/EGFP fused proteins were detected by fluorescent confocal laser
microscope on living HT-1080 cells 24 h after transfection. Scale bar: 10 mm. (C) Immunofluorescent staining of transfected HT-1080 cells by GFP
specific monoclonal antibody on paraformaldehide-fixed and Triton X-100 permeabilised cells. Scale bar: 10 mm. (D) The mRNA expression of
endogenous and recombinant syndecan-1 was examined by qRT-PCR with primer pairs specific for the cytoplasmic domain (SDC1-CD) and the
ectodomain (SDC1-ED) or EGFP cDNA (EGFP). Latter one detects transcrips from all three plasmids thus provides information on transfection
efficiency. In the course of relative quantification GAPDH served as reference gene, and the EGFP transfected sample as control. Results are expressed
as mean6s.d. (n=3), *p,0.05 versus control EGFP cells. Note, that the SDC-ED primers do not recognize the 78Sig cDNA, thus they detect only
endogenous syndecan-1 in 78Sig transfectants. (E) Relative syndecan-1 protein levels in the lysates and in the media of cell cultures by CD138 ELISA
that detects syndecan-1 with an ectodomain specific monoclonal antibody (n=3), *p,0.05. (F) Immunofluorescent staining of transfected HT-1080
cells by syndecan-1 ectodomain specific monoclonal antibody B-B4 on methanol-fixed cells. Identical exposure times and background corrections
were applied. Scale bar: 50 mm.
doi:10.1371/journal.pone.0039474.g001
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Plasmid Constructs
For the FullEGFP plasmid construct (Szila ´k Labor Ltd., Szeged,
Hungary), enhanced green fluorescent protein (EGFP) cDNA has
been cloned in frame with the C-terminus of full length human
syndecan-1. In case of the 78Sig plasmid construct (Szila ´k Labor
Ltd.), a truncated syndecan-1 cDNA, lacking the ectodomain with
the exception of the membrane proximal DRKE sequence, has
been cloned in frame with the C-terminus of EGFP (Figure 1A).
The host vector pEGFP-N1 (BD Biosciences, Clontech, Paolo
Alto, CA, USA) was used as negative control for overexpression
experiments. Plasmids coding for full length syndecans without an
EGFP tag were also generated in-house (syndecan-2) or obtained
(syndecan-1,Szila ´k Labor Ltd. and syndecan-4 [27]).
For gene silencing experiments, vector based RNA interference
(RNAi) was applied using the BLOCK-iT
TM Pol II miR RNAi
system (Invitrogen by Life Technologies, Carlsbad, CA, USA).
The inserts, containing the antisense target sequence (mature
miRNA RNAi sequence), a miRNA loop derived from miR-155,
and the sense target sequence with one base deletion were
designed with the BLOCK-iT RNAi Designer (Invitrogen). The
sense and antisense strands of the inserts were obtained as
conventional oligonucleotides and annealed to double strands.
Designed double strands were then cloned into the Block-iT
TM
pcDNA6.2-GW/EmGFP-miR Expression Vector (Invitrogen)
according to the supplied protocol (BLOCK-iT
TM Pol II miR
RNAi Expression Vector Kit with EmGFP). The system allows
fluorescent detection of successfully targeted cells. S1miRNA-a, -b
and S2miRNA-a, -b plasmids encoded artificial microRNAs
targeting human syndecan-1 or syndecan-2, respectively
(Table 1). Two microRNA coding constructs were designed for
each target. LacZmiRNA, supplied by the manufacturer, targeting
b-D-galactosidase was used as a negative control for the silencing
experiments.
Cell Culture and Transfection
HT-1080 human fibrosarcoma cells (ATCC number: CCL-121)
were grown in RPMI-1640 medium (Sigma-Aldrich, St Louis,
MO, USA) containing 10% foetal bovine serum (FBS, from
Sigma-Aldrich), and penicillin-streptomycin (100U and 100 mg/
mL, respectively). Cells were cultured in 75 cm
2 tissue culture
flasks (Sarstedt, Newton, NC, USA) at 37uC under a humidified
atmosphere containing 5% (v/v) CO2. Culture medium was
changed twice per week, and cells were regularly tested for
mycoplasma infection by PCR assay [28].
For transfection, 3610
5 HT-1080 cells were seeded into six-well
plates and incubated for approximately 24 hours to reach 60–80%
confluence. To achieve optimal transfection, 2 mL of FuGENE 6
transfection reagent (Roche, Basel, Switzerland) and 0.8 mgo f
plasmid DNA were diluted in 60 mL serum- and antibiotics-free
RPMI-1640 medium. After 15 minutes of incubation, the mixture
was added dropwise onto the cells preincubated in 1 mL of serum-
and antibiotics-free RPMI. After 4 hours of incubation, the
transfection mixture was removed from the cultures and replaced
with normal culture medium.
To obtain stable transfectants, cells were selected by addition of
Geneticin (G418, Roche) at a final concentration of 600 mg/mL,
or in case of microRNA-coding plasmids, 20 mg/mL blasticidin
(Invitrogen). Drug-resistant cells transfected with the BLOCK-iT
vectors were sorted for EGFP-positive cells by fluorescence-
activated cell sorting (FACS) using the BD FACSAria Flow
Cytometer (BD Biosciences).
Subcellular Localisation of Recombinant EGFP Fusion
Proteins
Distribution of syndecan-1/EGFP fusion proteins in living HT-
1080 cells was examined 24–48 h after transfection using the
MRC-1024 confocal laser scanning microscope (Bio-Rad, Hercu-
les, CA, USA). The instrument was equipped with a Kr/Ar Laser
and emission of signals was detected at 522616 nm.
Proliferation Assay
Stably transfected cells were seeded into 96-well plates at a
density of 5000 cells/well. To quantify cells, the sulforhodamine B
(SRB) colorimetric assay was used. This assay is based on the
measurement of cellular protein content. Cells were fixed with
10% (w/v) trichloroacetic acid and stained with SRB (Sigma-
Aldrich) for 30 minutes followed by repeated washing with 1% (v/
v) acetic acid to remove the excess dye. The protein-bound dye
was dissolved in a 10 mM Tris base solution and absorbance was
determined at 570 nm using Multiskan MS ELISA plate reader
(A.A. Lab Systems, Ramat-Gan, Israel). Doubling time of cells was
calculated from the log phase of their growth curves measured by
the SRB assay at 4, 24, 48 and 72 hours after seeding.
Chemotaxis Assay
HT-1080 cell migration was measured using a 48-well micro
chemotaxis chamber (Neuro Probe, Gaithersburg, MD, USA)
equipped with a 8 mm pore-size polycarbonate membrane filter
(Whatman, GE Healthcare Bio-Sciences Corp., Florham Park, NJ,
USA). Fifty mL of cell suspension (1610
6 cells/mL) in culture
medium containing 10% FBS was placed into the upper chamber.
Extracellular matrix (ECM) gel from Engelbreth-Holm-Swarm
murine sarcoma (Sigma-Aldrich) diluted in serum-free medium at
0.05 mg/mL was placed in the bottom chamber as chemoat-
tractant, except for the blank sample where it was omitted. After a
4-hour-long incubation in humidified atmosphere and 5% CO2 at
37uC, the chamber was disassembled and cells from the upper face
Table 1. List of recognition sequences targeted by silencer plasmids used.
Plasmid name Target sequence NCBI Reference Sequence Target position on ref. seq.
S1miRNA-a CCGCAAATTGTGGCTACTAAT NM_001006946.1 455–475
S1miRNA-b ACCAAACAGGAGGAATTCTAT NM_001006946.1 1298–1318
S2miRNA-a GGGAGCTGATGAGGATGTAGA NM_002998.3 789–809
S2miRNA-b CGAAGAGGATACAAATGTGTA NM_002998.3 990–1010
LacZ-miRNA GACTACACAAATCAGCGATTT – –
S1miRNA-a and -b are specific for syndecan-1, S2miRNA-a and -b target syndecan-2.
doi:10.1371/journal.pone.0039474.t001
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fixed and stained with Toluidine Blue (Sigma-Aldrich). The
amount of cells migrated through the membrane was quantified by
densitometry using the Kodak Image Station 4000MM (Care-
stream Health, Inc., Rochester, NY, USA) and software provided
by the manufacturer.
Animal Experiments and Lung Metastasis Model
All animal study protocols were conducted according to the
Semmelweis University guidelines for animal care. Animal studies
were approved by Budapest and Pest county Agricultural
Administrative Authority Directorate for the Safety of the Food
Chain and Animal Health, permit number 399/003/2005.
To generate spontaneous lung metastases, HT-1080 tumour
cells were transplanted into the foot pads of mice [29]. HT-1080
cells stably transfected with EGFP, FullEGFP or 78Sig were
injected into the right foot pads of five female severe combined
immunodeficient (SCID) mice per group (10
5 cells/mouse).
Tumour volume was measured in two dimensions using a digital
caliper and calculated according to Feldman J. [30] with the
following formula: V = p/661.63 (length 6 width)
3/2. For the
FullEGFP injected group average tumour volume reached 150
mm
3 at day 24, for the 78Sig group at day 29 and for the control
EGFP group at day 34. To prevent toxic effect of tumour necrosis,
tumour bearing legs were amputated when the average tumour
size in the group reached the volume of 150 mm
3. At the time of
amputation mice were anesthetised with ketamine (80 mg/kg)
combined with xylazine (12 mg/kg). All mice were sacrificed on
day 50 after inoculation. The percentage of total lung area
occupied by metastases was calculated by morphometrical analysis
of hematoxylin-eosin (HE) stained sections of the lungs in 5
randomly chosen planes using the Kodak Image Station 4000MM
and software provided by the manufacturer.
RNA Isolation and Quantitative RT-PCR
Transfected cells stably overexpressing EGFP, FullEGFP or
78Sig were cultured for 48 hours, then total RNA was isolated
using the RNeasy Mini Kit (Qiagen, Hilden, Germany), according
to the protocol provided by the manufacturer. The yield and
purity of the isolated RNA were estimated by an ND-1000
spectrophotometer (NanoDrop Technologies, Wilmington, DE,
USA). The integrity and size distribution of the total RNA purified
were analysed using Experion RNA Chips and the Experion
Automated Electrophoresis Station (Bio-Rad).
To prove that HT-1080 cells were successfully transfected with
syndecan-1 variants, quantitative reverse transcription PCR (qRT-
PCR) was performed. Complementary DNAs (cDNAs) were
generated from 1 mg of total RNA by M-MLV Reverse
Transcriptase kit (Invitrogen) according to the instructions of the
supplier. qRT-PCR was performed in the ABI Prism 7000
Sequence Detection System (Applied Biosystems by Life Tech-
nologies, Carlsbad, CA, USA), using primers at 1 mM final
concentration, and Power SYBRH Green PCR Master Mix
(Applied Biosystems by Life Technologies). The SDC1-CD primer
pair was designed to amplify the cytoplasmic domain region of
syndecan-1 cDNA, the SDC1-ED pair was specific for the
ectodomain, while the SDC2 primers were specific for syndecan-
2 (Table 2). TaqMan Gene Expression Assay for GAPDH was
used as reference (Applied Biosystems by Life Technologies). All
samples were run in triplicates in 20 mL reaction volume with
20 ng of cDNA/reaction. Results were obtained as threshold cycle
(CT) values. Expression levels were calculated by using the 2
2DDCT
method.
Oligoarray Analysis
Purified RNA samples were processed for oligoarray analysis
using the Cancer PathwayFinder Oligo GEArray (SABiosciences,
Qiagen, Hilden, Germany) representing 117 genes involved in
cancer. Two-and-a-half mg of total RNA was labelled with the
True-Labeling 2.0 Kit (SABiosciences), and hybridisation was
performed according to the manufacturer’s protocol.
CD138 ELISA and Western Blot
Total protein was extracted from cultures of HT-1080
transfectants and frozen primary tumour tissues. Primary tumours
were homogenised in liquid nitrogen followed by addition of 1 mL
of lysis buffer [20 mM Tris pH=7.5, 2 mM EDTA, 150 mM
NaCl, 1% Triton X-100, 2 mM sodium orthovanadate, 10 mM
sodium fluoride, 0.5% protease inhibitor cocktail (Sigma-Aldrich)].
Cultured cells were washed with phosphate buffered saline (PBS)
and lysed in 1 mL lysis buffer. Cells were scraped off and lysates
were transferred into microcentrifuge tubes. After brief sonication
and incubation on ice for 30 minutes, samples were centrifuged at
15,000 g for 20 minutes. The protein concentrations in the
supernatants were measured according to Bradford [31]. Media of
cultured cells were concentrated to J of the original volume using
the Amicon Ultra-15 Centrifugal Filter Unit with Ultracel-10
membrane (Millipore, Billerica, MA, USA).
The amounts of syndecan-1 in cultured cells, conditioned
media, and tumour lysates were measured using a CD138
sandwich ELISA kit (Diaclone, Gen-Probe Incorporated, San
Table 2. List of primers used.
Name of primer pair Primer sequences (59-39 orientation) primer position on ref. seq. NCBI Reference Sequence
EGFP F: ATCGAGCTGAAGGGCATCG 367–385 gb|GU112756.1|
R: CCTTGATGCCGTTCTTCTGCT 467–487 gb|GU112756.1|
SDC1-ED F: GCTGACCTTCACACTCCCCA 908–927 NM_001006946.1
R: CAAAGGTGAAGTCCTGCTCCC 1011–1031 NM_001006946.1
SDC1-CD F: GAAGAAGAAGGACGAAGGCAG 1225–1245 NM_001006946.1
R: CCTCCTGTTTGGTGGGC 1294–1310 NM_001006946.1
SDC2 F: AATGGACCCAGCCGAAGAG 978–996 NM_002998.3
R: CAGCAATGACAGCTGCTAGGAC 1051–1072 NM_002998.3
F: forward primer, R: reverse primer.
doi:10.1371/journal.pone.0039474.t002
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Samples were measured in triplicates.
For Western blotting, proteins were isolated as described above.
In case of syndecan-2 Western blots, additional heparitinase
digestion was performed as described before [32]. Twenty
micrograms of total protein was mixed with loading buffer
containing b-mercaptoethanol and incubated at 95uC for 5 min-
utes. Denatured samples were loaded onto 10% polyacrylamide
gels and were run for 30 minutes at 200 V on Mini Protean
vertical electrophoresis equipment (Bio-Rad). Proteins were
transferred to PVDF membranes (Millipore) by blotting for 16
hours with 75 mA at 4uC. Ponceau staining was applied to
determine the efficiency of protein transfer. Membranes were
blocked with 3% (w/v) non-fat dry milk (Bio-Rad) in Tris-buffered
saline (TBS) for 1 hour followed by incubation with primary
antibodies (Table S1) at 4uC for 16 hours. GAPDH served as
loading control. Membranes were washed 5 times with TBS
containing 0.5 v/v% Tween-20, then were incubated with
appropriate HRP-conjugated secondary antibodies (Dako,
Glostrup, Denmark) at room temperature for 1 hour. Signals
Figure 2. Effects of FullEGFP and 78Sig on the proliferation and chemotactic migration of HT-1080 cells. (A) Doubling times were
calculated from the log phase of growth curves (B) obtained from the SRB colorimetric assay. Values are expressed as mean6s.d. (n=8). (C) CDK2,
phospho-retinoblastoma (at T373 position) and GAPDH immunoblots of HT-1080 cells transfected with EGFP, FullEGFP or 78Sig. (D) Representative
fields of cyclin E immunocytochemistry (red) on cultured HT-1080 cells transfected with EGFP, FullEGFP or 78Sig. Scale bar: 20 mm. (E) Relative
amounts of migrated cells toward ECM proteins in a Boyden chamber after transfection with EGFP, FullEGFP or 78Sig. Values are shown as mean6s.d.
(n=5), *p,0.05 and **p,0.01. (F) Syndecan-2 and GAPDH immunoblots of cultured HT-1080 transfectants. Sdc-2 stands for syndecan-2 transfection.
(G) Results of flow cytometry after immunofluorescent staining of stable transfectants using the ZMD.308 antibody for syndecan-2. (H)
Immunofluorescent staining of methanol-fixed cells by the syndecan-2 specific antibody L-18 (red). Identical exposure times and background
corrections were applied. Scale bar: 50 mm. For (E and G) nuclei were counterstained with DAPI (blue).
doi:10.1371/journal.pone.0039474.g002
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4000 MM (Carestream Health, Inc.).
Phospho-receptor Tyrosine Kinase Array
Stably transfected HT-1080 cells were screened for 42 different
phosphorylated receptor tyrosine kinases (RTKs) using the
Proteome Profiler
TM antibody array (R&D Systems, Catalog
Number ARY001) following the manufacturer’s instructions.
Positive signals were captured and quantified by Kodak Image
Station 4000 MM.
Immunofluorescent Staining
For immunofluorescent staining, 3610
5 transfected cells were
seeded onto glass coverslips in 6-well plates and cultured for 24–48
hours, then fixed in methanol. Cryostat sections of the primary
tumours were also fixed in ice-cold methanol. Samples were then
washed in PBS, blocked with 5% (w/v) bovine serum albumin
(BSA) at 37uC for 30 minutes. After washing, samples were
incubated with the appropriate primary antibody (Table S1)
diluted in PBS, containing 1% (w/v) BSA at 37uC for 1.5 hours.
Appropriate fluorescent secondary antibodies were applied at
room temperature for 30 minutes. Nuclei were stained with 49,6-
diamidino-2-phenylindole (DAPI) or propidium iodide. Pictures
were taken by a Nikon Eclipse E600 microscope and Lucia
Cytogenetics version 1.5.6 software, or by an MRC-1024 confocal
laser scanning microscope. Equal exposure times and background
corrections were applied for all images.
Flow Cytometry
Cells were harvested with 5 mM EDTA (in PBS), and fixed in
ice cold ethanol for 5 minutes. Samples were then washed in PBS,
blocked with 3% (w/v) BSA in PBS at 37uC for 30 minutes. To
detect syndecans, cells were directly incubated with an Alexa
FluorH 647-conjugated specific antibody against syndecan-1 (clone
B-B4) or a non-conjugated syndecan-2 antibody (M-140, and
ZMD.308)(Table S1). ZMD.308 binding was visualised using a
Cy5 conjugated anti-rabbit antibody from Jackson ImmunoR-
esearch Laboratories Inc. (West Grove, PA, USA). Stained cells
were loaded onto a FACScalibur flow cytometer (BD Biosciences)
and quantitated with Cell Quest software (BD Biosciences). A
range of 5000-10,000 events were measured from all samples.
Statistical Analysis
Differences between means were evaluated using two-tailed
unpaired Student’s t-test after F-probe, or Mann-Whitney U-test.
x
2-test was applied for differences between various groups of in
vivo experiments. Statistical significance was considered at
p,0.05.
Results
EGFP-tagged Syndecan-1 Variants Express and Localise
to the Cell Membrane
Syndecan-1/EGFP plasmid vectors (Figure 1A) were stably
transfected into HT-1080 cells.
Recombinant chimeric syndecan-1/EGFP proteins were de-
tected in living cells by their green fluorescence, using confocal
laser microscopy 24 hours after transfection. Control cells
transfected with empty EGFP vector exhibited diffuse cytoplasmic
and nuclear fluorescence (not shown), whereas FullEGFP and
78Sig proteins localised to the cell membrane and the endomem-
brane system (Figure 1B). The green fluorescence of 78Sig cells
was less intensive than that of FullEGFP. Anti-GFP immunoflu-
orescent staining displayed similarly strong membrane signals
(Figure 1C).
FullEGFP Increases the Amount of Cell Surface-bound
and Soluble Syndecan-1, whereas 78Sig does not Affect
Expression or Shedding of Endogenous Syndecan-1
Results obtained from qRT-PCR using primers specific for
EGFP revealed that there were a significantly higher number of
transcripts of 78Sig, than those of FullEGFP in HT-1080
transfectants (Figure 1D). Accordingly, FullEGFP construct
induced a 6-fold, and 78Sig a 14-fold increase in total syndecan-
1 mRNA levels, when compared to the control EGFP, detected by
the SDC1-CD primer pair that is specific for the syndecan-1
cytoplasmic domain. The SDC1-ED primer pair amplifies only
the full length syndecan-1 cDNA whereas it is unable to recognise
the 78Sig transcript. This primer pair detected increased mRNA
levels only in the FullEGFP transfectants, indicating that the 78Sig
construct did not influence the expression of endogenous
syndecan-1 (Figure 1D).
In each microgram of total protein isolated from EGFP,
FullEGFP, and 78Sig transfectants and their conditioned cell
media 315613, 57068, 29468 and 5.560.02, 20.560.72,
5.060.06 nanograms of syndecan-1 could be detected, respec-
tively, using CD138 ELISA specific for the ectodomain. When
data were normalised to the EGFP controls, twice as much
syndecan-1 protein was found in the cell lysate and four times
more in the medium of FullEGFP transfectants, while no changes
in 78Sig transfectants have been detected (Figure 1E). These
results supported the data obtained by qRT-PCR.
Immunofluorescent staining on stable transfectants was per-
formed using the B-B4 antibody specific for the ectodomain of
syndecan-1 (Figure 1F). In comparison with the EGFP transfected
cells, only FullEGFP cells showed stronger staining, fully
supporting the ELISA and qRT-PCR results.
FullEGFP and 78Sig Both Increase Proliferation and
Chemotactic Migration –Involvement of Cyclin E1/CDK2
Complex and Syndecan-2
Proliferative activity of transfectants was measured by the SRB
assay, and doubling times (Figure 2A) were calculated from the log
phase of proliferation curves (Figure 2B). Both syndecan-1
constructs stimulated proliferation of HT-1080 cells. While for
control EGFP the doubling time was 25.660.2 h, it was reduced
to 21.761.5 by FullEGFP and to 21.062.0 h by 78Sig and these
differences were statistically significant (p,0.05 and p,0.01,
Figure 2A).
Oligonucleotide arrays were performed in order to characterise
signalling activities transmitting the effects of syndecan-1 in HT-
1080 cells. Primarily, genes that regulate the G1/S transition of
the cell cycle showed altered mRNA expression, including elevated
CDK2 and cyclin E1 mRNA levels (data not shown). The increase
of CDK2 expression was verified by Western blotting (Figure 2C),
and cyclin E1 expression by immunofluorescent staining
(Figure 2D). CDK2 when in complex with cyclin E1 phosphor-
ylates retinoblastoma 1 (Rb). Thus, levels of Rb phosphorylated at
Thr373 were evaluated by immunoblotting. Phosphorylation of
Rb protein was enhanced in both FullEGFP and 78Sig cells
relative to the EGFP control (Figure 2C).
To study the effects of full length and truncated syndecan-1 on
the migration ability of HT-1080 cells, the Boyden chemotaxis
assay was performed. Directed migration of HT-1080 cells
transfected with FullEGFP and 78Sig towards ECM proteins
was significantly higher than that of EGFP control used as baseline
Syndecans and HT-1080 Cells
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intensively, significantly more than FullEGFP did (p,0.05)
(Figure 2E). In addition, using the ZMD.308 antibody an increase
in syndecan-2 protein expression was found in cells overexpressing
full length or truncated syndecan-1, detected by Western blotting
(Figure 2F) and also by FACS analysis. Fluorescent signals of the
antibody were increased by 1.7 fold by FullEGFP and by 2.4 fold
by the 78Sig (Figure 2G). These upregulations of syndecan-2 were
also detected by immunofluorescent staining where L-18 antibody
was used to mark syndecan-2 (Figure 2H).
Syndecan-1 Enhances Migration and Proliferation in
Cooperation with Syndecan-2
Overexpression of full length or truncated syndecan-1 resulted
in subsequent increase in syndecan-2 expression (Figure 2F, 2G,
2H). As overexpression of syndecan-2 has been shown to
significantly increase chemotaxis of HT-1080 cells [22], in the
current report we tested a functional relationship between
syndecan-1 and syndecan-2.
To refine the hierarchy of syndecans in this context, vector
based RNA interference assays using artificial microRNA coding
plasmids specific for syndecan-1 and syndecan-2 (S1miRNA-a
and -b, and S2miRNA-a and -b) were utilised. LacZmiRNA
plasmid served as control (Table 1). S1miRNA-a and -b resulted
in a significant decrease in syndecan-1 expression to 56% and
33%, respectively (p,0.05), while no significant changes in the
expression of syndecan-2 was detected. S2miRNA-a and -b
reduced syndecan-2 expression to 72% and 43%, respectively.
Silencing effects were evidenced by qRT-PCR using the SDC1-
ED and SDC2 primer pairs and GAPDH for reference gene
(Figure 3A). Syndecan-1 protein levels also decreased by
S1miRNA-a and -b, measured by FACS using direct labelled
B-B4 antibody (Figure 3B). Reduction in syndecan-2 expression
by S2miRNA-a and -b was noted using the syndecan-2 specific
M-140 antibody (Figure 3C). Only S2miRNA-b affected
doubling times increasing it significantly (Figure 3D). Synde-
can-2 silencing significantly inhibited chemotaxis of HT-1080,
whereas syndecan-1 knock-down had no such effect (Figure 3E).
To test the importance of syndecan-2 in the highly malignant
phenotype of syndecan-1 overexpressing fibrosarcomas,
S2miRNA-a was co-transfected with 78Sig or an EGFP empty
vector control. The presence of 78Sig transcripts in ‘‘S2miRNA-a
+78Sig’’ stable transfectants was confirmed by RT-PCR, using the
EGFP forward and the SDC1-CD reverse primers, while
‘‘S2miRNA-a + EGFP’’ and LacZmiRNA control cells were
negative for the transcript. For positive control, GAPDH primers
were used (Figure 4A). The expression of syndecan-2 was
successfully reduced in both ‘‘S2miRNA-a +78Sig’’ and
‘‘S2miRNA-a + EGFP’’ cells, compared to LacZmiRNA control
cells, as evidenced by FACS using the M-140 antibody (Figure 4B).
When co-transfected with the S2miRNA-a construct, 78Sig
increased neither the proliferation rate nor the chemotaxic ability
of the cells (Figure 4C, D). Chemotaxis was inhibited in both
‘‘S2miRNA-a + EGFP’’ and ‘‘S2miRNA-a +78Sig’’ cells, com-
pared to that in LacZmiRNA cells (Figure 4D).
FullEGFP and 78Sig Promotes Malignancy of HT-1080
Cells in Vivo
To estimate in vivo malignancy of the stable transfectants, they
were injected into foot pads of SCID mice (5 per group). Twenty-
four days after injection, the average volume of primary tumours
increased as follows: EGFP (35.0611.7 mm
3), FullEGFP
(156.3686.0 mm
3), and 78Sig (92.8644.2 mm
3) (Figure 5A).
After 1 day, significant differences between the EGFP control and
the syndecan-1 transfectant groups were found in the size of
primary tumours by t-test (*p,0.05). Moreover, in the FullEGFP
group, a significantly higher number of primary tumours reached
the size of 150 mm
3 than those in the 78Sig group, according to
Figure 3. Effects of syndecan-1 and -2 gene silencing on the proliferation and migration of HT-1080 cells. (A) Relative mRNA levels
of syndecan-1 (SDC1) and syndecan-2 (SDC2) in HT-1080 cells transfected with artificial microRNA coding plasmids, specific for b-D-galactosidase
(LacZ), syndecan-1 (S1miRNA-a and -b) or syndecan-2 (S2miRNA-a and -b). Values are expressed as mean6s.d calculated by relative quantification
of three independent qRT-PCR results using GAPDH as reference gene and LacZmiRNA control as calibrator. (B, C) Results of flow cytometry after
immunofluorescent staining of stable transfectants using the B-B4 antibody for syndecan-1 or the M-140 antibody for syndecan-2. (D) Doubling
times of stable transfectants. Values are expressed as mean6s.d. (n=8). (E) Relative amounts of migrated HT-1080 stable transfectants in a 48-well
Boyden chamber. The chemoattractants were ECM proteins. Values are expressed as mean6s.d. (n=5), *p,0.05 versus control LacZmiRNA cells.
doi:10.1371/journal.pone.0039474.g003
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2-test (#p,0.05) indicating that the FullEGFP construct
promoted proliferation more effectively (Table 3). While the EGFP
transfected group required 34 days to reach 150 mm
3 average
tumour volume, for 78Sig and FullEGFP it was only 29 and 24
days, respectively. Fifty days after injection, mice were sacrificed
and the area fraction of lung metastases (Table 4) was calculated
by morphometric analysis of 5 different, random planes of HE-
stained sections (Figure 5B). In the EGFP group only one animal
developed metastasis in its lung with negligible size. This number
was 4 and 3 for FullEGFP and 78Sig groups, respectively (Table 4).
The area of lung metastases in animals having tumours in the lung
was 19.92616.60% and 28.76622.97% for FullEGFP and 78Sig,
respectively, significantly more than the 0.0260.15% of the
control EGFP (p,0.05).
Immunofluorescent staining, Western blot and qRT-PCR were
performed to explore whether molecular changes underlying the
increased in vitro cell proliferation rate were detectable in primary
tumours as well. Western blot assays (Figure 5C) confirmed
increased CDK2 expression and enhanced retinoblastoma phos-
phorylation at T373. Furthermore, elevated transcription and
protein expression of syndecan-2 in FullEGFP and 78Sig
expressing tumours was confirmed by qRT-PCR (Figure 5D)
and immunofluorescent staining (Figure 5E).
In order to confirm the presence of recombinant proteins in
vivo, qRT-PCR assay with EGFP primers, and immunofluores-
cent staining for GFP were performed on primary tumours.
Results of qRT-PCR relative quantification suggested that both
syndecan-1/EGFP fusion constructs were transcribed (Figure
S1A). Transfection with FullEGFP resulted in a 6-fold, and with
78Sig a 20-fold increase in syndecan-1 mRNA levels, compared to
the control EGFP transfectant, using the SDC1-CD primer pair.
The SDC1-ED primer pair detected increased mRNA levels in
FullEGFP transfectants only (Figure S1B). To detect the recom-
binant proteins in primary tumours, immunofluorescent staining
for GFP was performed (Figure S1C top row). FullEGFP
expressing primary tumours exhibited stronger signals than those
expressing EGFP or 78Sig, visualised by immunostaining with the
B-B4 antibody specific for the syndecan-1 ectodomain (Figure S1C
bottom row). These data confirmed the results found in cell
cultures.
Syndecan-1, -2, and -4 Stimulates Chemotaxis but only
Syndecan-1 Enhances Proliferation of HT-1080 Cells
To expand the scope of our study, (and exclude possible
interferences caused by the GFP-tag), HT-1080 strains stably
expressing full length syndecan-1, -2, and -4 without a GFP-tag
were established and their behaviour was tested in vitro.
Syndecan-1 significantly reduced doubling time from
24.8460,26 hours to 21.0760,65 hours, compared with EGFP
control cells. This effect was also significant when compared to
untransfected wild type (wt) cells (p,0.05). Overexpression of
Figure 4. Truncated syndecan-1 does not affect the proliferation or the migration of HT-1080 cells if syndecan-2 is silenced. (A)
Detection of transcripts of the 78Sig construct in double transfectants after Geneticin selection by RT-PCR using the EGFP forward and the SDC1-CD
reverse primers that produce a 550 bp long amplicon. Agarose electroforetograms the PCR products of these primers. GAPDH was used as positive
control. S2miRNA-a + EGFP: the S2miRNA-a was co-transfected with the EGFP control vector. S2miRNA-a +78Sig: S2miRNA-a was co-transfected with
the 78Sig vector. (B) Cell sorting results after immunofluorescent staining of double transfectants using the M-140 antibody specific for syndecan-2.
(C) Doubling times of double transfectants. Values are expressed as mean6s.d. (n=8). (D) Relative amounts of migrated HT-1080 stable transfectants
in 48-well Boyden chamber. Chemoattractants were ECM proteins. Values are expressed as mean6s.d. *p,0.05 and **p,0.05 versus LacZmiRNA cells
(n=5).
doi:10.1371/journal.pone.0039474.g004
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time only in comparison to EGFP cells (p,0.05), but not wt
(Figure 6A).
Overexpression of either syndecan paralogue uniformly in-
creased the migratory ability of HT-1080 cells up to two fold
(p,0.01). Migration of EGFP control cells did not differ
significantly from that detected using wt cells (Figure 6B).
Implication for Insulin-like Growth Factor 1 Receptor
(IGF1R) and Ets-1 Transcription Factor in the Cooperation
of Syndecan-1 and Syndecan-2
To identify key signalling events underlying the observed
induction of syndecan-2 by syndecan-1 overexpression in HT-
1080, EGFP, FullEGFP, 78Sig and Sdc-2 stable transfectants were
assayed on a phospho-receptor tyrosine kinase (pRTK) array and
by Western blot.
According to these initial experiments two of the 42 RTKs
investigated, IGF1R and Axl, showed considerable changes in
their phosphorylation levels. When compared to the EGFP control
cells, both receptors were significantly hyperphosphorylated in
FullEGFP expressing cells, while only IGF1R showed an
enhancement in 78Sig and Axl a moderate but significant
reduction in the Sdc-2 transfectants (Figure 7A). MAP kinases
p44-42 and p38 were hyperphosphorylated in FullEGFP, 78Sig as
well as in Sdc-2 cells (Figures 7B and 7C). There were no changes
in the phosphorylation of AKT (data not presented) while the
expression of Ets-1 transcription factor was increased only in
FullEGFP and 78Sig cells (Figure 7C and 7D).
Discussion
Syndecan-1 is expressed principally in epithelial tissues; hence
studies aiming to address its role in malignancies examine mostly
carcinomas. Syndecan-1 modulates the biological behaviour of
parenchymal cells in several types of carcinomas. Additionally, its
Figure 5. Effects of FullEGFP and 78Sig on the malignancy of HT-1080 cells in vivo. (A) Size of primary tumours in the footpads of SCID
mice on the 24
th day after injection of HT-1080 cells expressing EGFP, FullEGFP or 78Sig. Photographs and results of morphometric analysis are
shown. *p,0.05 (t-test), #p,0.05 (x
2-test)(n=5). (B) Histological appearance of lung metastases (arrows) of HT-1080 transfectants. Images do not
represent the area percentage of metastases; rather, the only one small EGFP tumour found is shown. HE-stained sections are shown, scale bar:
200 mm. (C) CDK2, phospho-retinoblastoma (at T373 position) and GAPDH immunoblots from HT-1080 primary tumours stably expressing EGFP,
FullEGFP or 78Sig. (D) Relative syndecan-2 mRNA levels of the transfectants. Values are expressed as mean6s.d calculated by relative quantification
of three independent qRT-PCR results using GAPDH as reference gene and EGFP transfected control as calibrator. *p,0.05 (non-parametric Mann-
Whitney test) compared to EGFP control cells. (E) Immunofluorescent staining of methanol-fixed frozen sections by the syndecan-2 specific antibody
L-18. Identical exposure times and background corrections were applied Scale bar: 50 mm.
doi:10.1371/journal.pone.0039474.g005
Table 3. Size of primary tumours on the 24th day after
inoculation of stably transfected HT-1080 cells (mm
3).
Mouse No. EGFP FullEGFP 78Sig
1 38.9 154.4 81.1
2 32.6 74.9 68.3
3 28.4 241.5 83.0
4 22.2 66.7 61.2
5 52.9 243.9 170.1
HT-1080 cells transfected with the corresponding plasmid construct were
injected into the foot pads of 5 mice. The volume of primary tumours was
measured for all mice.
doi:10.1371/journal.pone.0039474.t003
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[33,34,35,36,37,38]. Recently the number of studies focusing on
syndecan-1 in tumours of mesenchymal origin rapidly increases.
In the present study, we demonstrated that overexpression of
either full-length or truncated syndecan-1 lacking the ectodomain
enhances proliferation, migration and spontaneous metastasis
formation ability using the human fibrosarcoma cell line HT-
1080. Although we provide evidence that syndecan-1, syndecan-2
and -4 uniformly stimulate chemotactic migration of HT-1080
cells, according to our studies only syndecan-1 promotes
proliferation when overexpressed.
We confirmed that both full length and truncated syndecan-1/
EGFP fusion proteins appear on the cell surface. Although the
green fluorescence of 78Sig is less intensive than that of FullEGFP,
the truncated variant is expressed in a significantly higher level.
The two constructs enhanced chemotaxis in different extents
reflecting their different expression levels. It is important to note,
that FullEGFP exert the same effects as the untagged full length
syndecan-1, suggesting that the EGFP-tag on the cytoplasmic
domain does not interfere with the cellular processes we
investigated. Thus, the increasingly significant effect of truncated
syndecan-1 on syndecan-2 expression and on cell migration is
explained by its higher level of expression.
The measurement of ectodomain levels revealed that overex-
pression of 78Sig influenced neither expression nor shedding of
endogenous syndecan-1. Overexpression of FullEGFP resulted in
an increased amount of syndecan-1 fragments on the cell surface
and consequently in the medium. Thus, putatively, transfection
with either construct may result in the accumulation of syndecan-1
lacking the ectodomain. According to Endo [39], the cleavage of
syndecan-1 ectodomain enhances migration of HT-1080 cells.
Others described that a mutant syndecan-1, unable to shed,
abolishes the pro-migratory role of syndecan-1 [40]. In support to
these findings, we showed that syndecan-1 enhances cell migration
in HT-1080 independently of the presence of its ectodomain.
An interesting cross-talk between syndecan-1 and -2 was found
in the migration of HT-1080 cell line. According to Park [22],
overexpression of syndecan-2 stimulates migration of these cells.
We confirmed that transfection of syndecan-2 increase chemotac-
tic migration of HT-1080 cells. Moreover, in our case migration
toward ECM proteins was also stimulated by syndecan-1
transfection and additionally, syndecan-2 was simultaneously
upregulated. Chemotaxis of HT-1080 was suppressed after
syndecan-2 silencing, while downregulation of syndecan-1 had
no such effect. The 78Sig construct was not able to exert its
migration stimulating effect when co-transfected with a syndecan-
2 silencer construct. This result proves, that syndecan-2 is a key
player in the pro-migratory effect of syndecan-1. That is,
syndecan-2 should be situated downstream of syndecan-1 in the
motility signal cascade. Similar cooperation was found by silencing
techniques between syndecan-2 and -4 in actin stress fibre
formation in lung cancer cell lines P29 and LM66-H11 [41], or
between syndecan-1 and syndecan-4 in the migration of dendritic
cells after their phospholipid induced maturation [42]. Interest-
ingly, overexpression but not silencing of syndecan-1 affected
syndecan-2 expression and consequently migration of HT-1080.
Syndecan-2 appears to have a basic threshold level that cannot be
reduced by syndecan-1 silencing. The reason to this phenomenon
may be that the linkage between syndecan-1 and -2 is indirect. We
Table 4. The area percentage of lung metastases.
area percentage of lung metastases
group
mouse
No. plane 1 plane 2 plane 3 plane 4 plane 5
EGFP 1 0,00 0,00 0,00 0,00 0,00
2 0,00 0,00 0,00 0,00 0,00
3 0,00 0,00 0,00 0,00 0,00
4 0,00 0,00 0,00 0,00 0,00
5 0,46 0,00 0,00 0,00 0,00
FullEGFP 1 0,00 0,00 0,00 0,00 0,00
2 35,34 12,53 20,08 14,90 21,48
3 58,69 0,00 56,52 0,00 50,45
4 19,55 3,78 3,08 4,64 12,55
5 0,00 0,00 0,12 1,87 0,00
78Sig 1 65,29 41,30 53,31 48,92 56,39
2 0,00 0,00 0,00 0,00 0,00
3 58,45 10,37 37,41 17,76 41,25
4 0,00 0,00 0,00 0,00 0,00
5 0,91 0,00 0,00 0,00 0,00
Mice were sacrificed on the 50th day after injection of HT-1080 cells into their
foot pads expressing EGFP, FullEGFP or 78Sig. Area percentage referring to the
area fractions of lung metastases were calculated by morphometrical analysis of
hematoxylin-eosin stained sections of the lungs in 5 random planes.
doi:10.1371/journal.pone.0039474.t004
Figure 6. Effects of syndecan-1, -2 and -4 overexpression on the proliferation and migration of HT-1080 cells. (A) Doubling times of
stable transfectants were calculated from the log phase of growth curves obtained from SRB colorimetric assays. Values are expressed as mean6s.d.
(n=8). (B) Relative amounts of migrated cells toward ECM proteins in a Boyden chamber. Values are shown as mean6s.d. (n=5). (A-B) EGFP denotes
cells transfected with the empty pEGFP-N1 vector. Sdc-1, Sdc-2 and Sdc-4 refer to syndecan-1, -2 and -4 with no EGFP-tag, respectively, and wt to
untransfected wild type (wt) cells. Symbols are *p,0.05 versus EGFP, **p,0.01 versus EGFP, #p,0.05 versus wt, and ##p,0.01 realtive to wt.
doi:10.1371/journal.pone.0039474.g006
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molecules transmit the effect of syndecan-1 on syndecan-2
expression. This presumption is supported by the observation that
syndecan-1 increases syndecan-2 expression at transcription level
as well (Figure 5D). Nevertheless, the promoter of syndecan-2 is
certainly regulated also by other factors, not only by syndecan-1.
In addition, others found in STAV-AB mesothelioma cells that
transfection of syndecan-1– contrary to the case in HT-1080–
downregulates syndecan-2 expression [43].
It is more difficult to identify the relation of syndecan-1 and -2
in the context of cell proliferation than that in migration. The
reason of this may due to the less intensive effect of syndecan-1
overexpression on cell proliferation than that on cell migration.
Overexpression experiments revealed that only syndecan-1
stimulates proliferation significantly in itself, syndecan-2 does
not, suggesting that syndecan-1 has a distinct proliferation
enhancing effect independent of syndecan-2. Nevertheless, silenc-
ing of syndecan-2 slightly inhibited the proliferation, and was able
to inhibit the proliferative effect of the 78Sig construct, suggesting
the prominent role of syndecan-2 in these processes. Apparently
simultaneous overexpression of syndecan-1 and -2 is needed to
stimulate proliferation of HT-1080 cells effectively.
In addition to their identical effects, both FullEGFP and 78Sig
affected expression or phosphorylation of mostly the same genes
involved in cell cycle regulation or migration suggesting similar
mechanisms of action. In the background of increased cell
proliferation after FullEGFP or 78Sig transfection, we detected
upregulation of cyclin E1 as well as increased phosphorylation of
Rb protein. Phosphorylation of Thr373 in Rb can be accom-
plished by the CDK2 cyclin E1 complex, and this phosphorylation
alone is sufficient to inactivate the Rb protein [44]. Our findings
suggest that transfection of syndecan-1 causes hyperphosphoryla-
tion of Rb by the CDK2 - cyclin E1 complex, an event that
contributes to the accelerated proliferation of HT-1080. Treat-
ment of HT-1080 cells with PD 98059 MAPK inhibitor leads to
inhibition of the CDK2 - cyclin E1 complex and arrests the cell
cycle in G1 phase [45] indicating the prominent role of this
complex in HT-1080 cell proliferation.
Interestingly, in STAV-AB malignant mesothelioma and B6FS
fibrosarcoma cells overexpression of the same full length and
truncated syndecan-1 constructs exhibit opposite effects, causing
reduced cell proliferation by the elongation of G1 and S phases of
the cell cycle [43] and retarded migration [46]. These studies
together with our work show that syndecan-1 can either accelerate
or inhibit motility and cell cycle of mesenchymal cells even in the
absence of the ectodomain, reflecting the dual role of syndecan-1
in mesenchymal tumours. This property of the three cell lines
analyzed herein renders them a useful model in the future to
unfold complex nature of syndecan-1 in malignancies.
To better understand the regulation of syndecan-2 expression
by syndecan-1, alterations in expression or phosphorylation levels
of various signal molecules were studied., These events occur only
upon syndecan-1 overexpression and not when syndecan-2 is
overexpressed. The receptor tyrosine kinase IGF1R and the
transcription factor Ets-1 matched this criterion. Syndecan-1 has
been demonstrated to interact with and activate IGF1R [47]. Ets-1
is a potential transcription factor to IGF1R [48], and it is involved
in tumour invasion and metastasis [49] processes also regulated by
syndecan-2 in HT-1080 cells. Surprisingly phosphorylation of
p44/42 and p38 was stimulated by both syndecan-1 and -2
although proliferation was stimulated only by syndecan-1. This
suggests that syndecan-1 could stimulate proliferation through an
alternative mechanism that is MAP kinase independent. We have
Figure 7. Candidates in the molecular mechanism of the cooperation between syndecan-1 and syndecan-2. (A) Results of pRTK array.
Relative extents of IGF1R and Axl phosphorylation in HT-1080 transfectants. Values are expressed as mean6s.d. *p,0.05 versus control EGFP cells
(n=3). (B and C) Representative immunoblots from HT-1080 cells stably expressing EGFP, FullEGFP, 78Sig or Sdc-2. Antibodies used are listed in Table
S1. (D) Results of densitometry of western blots. Values are expressed as mean6s.d. *p,0.05 by t-test.
doi:10.1371/journal.pone.0039474.g007
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alternative experimental design protocols.
The significant increase in the motility of FullEGFP and 78Sig
transfectants found in vitro by chemotaxis assays is in good
accordance with their elevated in vivo metastatic potential. We
found an increase in the number of mice developing lung
metastasis and in the area fraction of metastases both in the
FullEGFP and 78Sig groups.
In addition to the numerous similarities in the behaviour of full
length and truncated syndecan-1 transfectants, some differences
were also observed. Although the presence or absence of the
ectodomain did not influence the proliferation enhancing effect of
syndecan-1 in cell culture, in our mouse model the FullEGFP
transfected tumours grew faster than the 78Sig expressors. The
increased in vivo proliferation of these transfectants appears to be
independent of syndecan-2 expression as FullEGFP cells contained
less syndecan-2 than those expressing 78Sig. This suggests an
additional, yet inidentified mechanism of full length syndecan-1
regulating HT-1080 proliferation in the presence of the ectodo-
main. Potentially this process is elicited by the tissue microenvi-
ronment.
Taken together, this work is the first to present syndecan-1
playing a tumour promoter role in a mesenchymal tumour cell
line, a process that progreses through the cooperation of syndecan-
1 and syndecan-2.
Supporting Information
Figure S1 Detection of EGFP and syndecan-1 in the
primary tumours. (A) mRNA expression of EGFP by qRT-
PCR normalised to GAPDH levels by relative quantification.
Results are expressed as mean6s.e.m. relative to EGFP control
(n=2). (B) mRNA expression of syndecan-1 was examined by
qRT-PCR with primer pairs specific for the cytoplasmic domain
(SDC1-CD) and the ectodomain (SDC1-ED) the control was the
EGFP in the course of relative quantification. Results are
expressed as mean6s.d. (n=3), *p,0.05 versus control EGFP
cells. (C) Immunostaining on frozen sections with anti-GFP
antibody (top row), or with the B-B4 antibody specific for
syndecan-1 (bottom row). Images were captured by confocal laser
microscopy and were handled equally applying same background
correction. Scale bar: 50 mm.
(TIF)
Table S1 Primary antibodies applied.
(DOC)
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